These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18261626)

  • 1. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
    Murphy KM; Chen F; Clark DP
    Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression and role of serum response factor in papillary carcinoma of the thyroid.
    Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
    Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
    Nasser SM; Pitman MB; Pilch BZ; Faquin WC
    Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
    Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
    Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma.
    Koo JS; Shin E; Hong SW
    APMIS; 2010 Oct; 118(10):744-52. PubMed ID: 20854468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
    Eszlinger M; Paschke R
    Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
    Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
    Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
    El Demellawy D; Nasr AL; Babay S; Alowami S
    Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.
    Jarzab B; Wiench M; Fujarewicz K; Simek K; Jarzab M; Oczko-Wojciechowska M; Wloch J; Czarniecka A; Chmielik E; Lange D; Pawlaczek A; Szpak S; Gubala E; Swierniak A
    Cancer Res; 2005 Feb; 65(4):1587-97. PubMed ID: 15735049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
    Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
    Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the clinical application of thyroid cancer biomarkers.
    Shibru D; Chung KW; Kebebew E
    Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
    Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
    Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
    Cvejic D; Savin S; Petrovic I; Selemetjev S; Paunovic I; Tatic S; Havelka M
    Exp Oncol; 2005 Sep; 27(3):210-4. PubMed ID: 16244583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
    Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
    Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
    Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
    Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
    Simms A; Jacob RP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
    Magro G; Schiappacassi M; Perissinotto D; Corsaro A; Borghese C; Belfiore A; Colombatti A; Grasso S; Botti C; Bombardieri E; Perris R
    J Pathol; 2003 Jul; 200(3):357-69. PubMed ID: 12845632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.